Senzime AB (SNZZF) Stock Price & Analysis
SNZZF Stock Chart & Stats
- Day’s Range
- $0.24 - $0.24
- 52-Week Range
- $0.24 - $0.67
- Previous Close
- $0.24
- Volume
- N/A
- Average Volume (3M)
- 6,523
- Market Cap
- $54.22M
- Enterprise Value
- $426.15M
- Total Cash (Recent Filing)
- $28.71M
- Total Debt (Recent Filing)
- $20.95M
- Price to Earnings (P/E)
- ―
- Beta
- 0.21
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Sensor Revenue
The high recurring share links revenue to the installed system base and procedure activity, supporting visibility beyond one-time monitor sales. Strong sensor growth also indicates increasing utilization and creates an attractive consumables-led model that can compound as more systems are deployed.
Established Clinical Reach
A broad installed base and substantial clinical usage provide evidence of product acceptance and a foundation for repeat consumables revenue. This reach can also support customer references, utilization growth, and expansion into the stated opportunity of more than 400,000 operating rooms.
Improving Product Economics
Higher gross margin and a lower operating cost base improve the economics of incremental revenue and provide a clearer route toward operating leverage. Although the reported margin included tariff repayments, the normalized level still represents materially stronger product economics than previously reported.
Bears Say
Deep Ongoing Losses
The company remains far from sustainable profitability despite revenue growth and better gross margin. Large operating and net losses indicate that the current cost structure still exceeds the revenue base, leaving execution dependent on further scale, continued expense control, and successful margin conversion.
Persistent Cash Burn
Continued cash consumption reduces financial flexibility and means growth has not yet become self-funding. Even with improved quarterly cash burn, the trailing pattern suggests the business may require financing if the planned cash-flow inflection is delayed or operating losses remain elevated.
Slow Commercial Conversion
Slower monitor conversions can delay installed-base expansion, which in turn postpones the recurring sensor revenue that supports the business model. Extended purchasing cycles and gradual adoption also make revenue timing less predictable and could lengthen the path to scale and profitability.
SNZZF FAQ
What was Senzime AB’s price range in the past 12 months?
What is Senzime AB’s market cap?
When is Senzime AB’s upcoming earnings report date?
How were Senzime AB’s earnings last quarter?
Is Senzime AB overvalued?
Does Senzime AB pay dividends?
What is Senzime AB’s EPS estimate?
How many shares outstanding does Senzime AB have?
What happened to Senzime AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Senzime AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Senzime AB
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Philip Siberg
- Employees
- 59
- Website
- senzime.com
- Address
- Verkstadsgatan 8, Uppsala, UP, 753 23, SE
Senzime AB (SNZZF) Earnings & Revenues
SNZZF Earnings Call
Earnings Call SentimentPositive
The call was strongly constructive. Senzime reported renewed growth, 43% sensor growth, a record 74% gross margin, lower operating expenses, materially improved EBITDA and cash flow, secured financing, and a reiterated target of positive cash flow within Q4. The main challenges were delayed U.S. deal closures, weaker monitor sales, no Q3 TetraGraph-as-a-Service contracts, ongoing market adoption work, and pending South Korean regulatory approval.
View all SNZZF earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 4 | 3 | 3 |
| Moving Averages | 1 | 1 | 10 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:PAXPaxman AB | ||
| SE:SCIBSciBase Holding AB | ||
| SE:BACTI.BBactiguard Holding AB | ||
| SE:ACARIXAcarix AB | ||
| SE:SEDANASedana Medical AB |








